Abstract: Provided is a stable formulation of a human papillomavirus virus-like particle vaccine. The stable formulation is composed of a human papillomavirus virus-like particle, a buffer solution, an osmotic pressure regulator, a surfactant and an aluminum adjuvant, wherein the components of the vaccine comprise HPV virus-like particles assembled by L1 proteins of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and one or more HPV virus-like particles assembled by L1 proteins of other pathogenic HPV types. The formulation can enhance the stability of the vaccine and prolong the validity period of the vaccine in an aqueous formulation.